Pharma BD Deal Intelligence

Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd.

2026 · Licensing/Option · Complete

Canadian commercialization of an approved aflibercept biosimilar

Teva Pharmaceutical Industries and Samsung Bioepis entered a license and commercialization agreement for Opuviz, a biosimilar referencing Eylea (aflibercept), in Canada. Samsung Bioepis is responsible for registration and manufacture of the product while Teva Canada is responsible for commercialization. Opuviz received Health Canada approval in October 2025 across retinal indications including neovascular AMD, diabetic macular edema, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. Financial terms were not disclosed.

Key facts

Announced Jul 09, 2026
Deal type Licensing/Option
Therapeutic area Ophthalmology
Indications Neovascular age-related macular degeneration, Diabetic macular edema, Macular edema secondary to retinal vein occlusion, Myopic choroidal neovascularization
Key assets Opuviz (aflibercept biosimilar, referencing Eylea)
Mechanism Anti-VEGF recombinant fusion protein (aflibercept biosimilar)

Related deals — scored

Deal	Year	Value	Outcome
Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. (this deal)	2026	—	51
Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals	2015	$3.5B	86
Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical	1995	—	82
Teva Pharmaceutical Industries Ltd. / Sicor Inc.	2003	$3.4B	68
Teva Pharmaceutical Industries Ltd. / IVAX Corporation	2006	$7.4B	63
Teva Pharmaceutical Industries Ltd. / Novopharm Limited	2000	$600M	62
Teva Pharmaceutical Industries Ltd. / Ivax Corporation	2005	$7.4B	62

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2026 deals · Teva Pharmaceutical Industries Ltd. deals · Ophthalmology deals